Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Thomas Filleron"'
Autor:
Leonor Chaltiel, Pierre Gazda, Benjamin Vairel, Thomas Filleron, Emilien Chabrillac, Agnès Dupret-Bories, Guillaume de Bonnecaze, Sébastien Vergez, Clément Gauche
Publikováno v:
European Archives of Oto-Rhino-Laryngology. 279:457-466
Transoral robotic surgery (TORS) as a first-line therapy has been well-documented but evidence is missing regarding salvage therapy. The aim of this study is to compare the oncological and functional outcomes of TORS as a primary and salvage therapy.
Autor:
Raphael Lopez, Sébastien Vergez, Amélie Lusque, Nicolas Meyer, Thomas Filleron, Jérôme Sarini, Emilien Chabrillac, Zoé Cavallier
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 13, Pp 1241-1245 (2019)
Ten to fifty percent of high-risk cutaneous squamous cell carcinoma may potentially metastasize. However, the concept of sentinel lymph node biopsy remains controversial for cutaneous squamous cell carcinoma. The aim of this study was to identify pro
Autor:
Bastien Cabarrou, Christine Chevreau, Tom Lesluyes, Muriel Mounier, Angélique Massoubre, Sophie Le Guellec, Muriel Poublanc, Thibaud Valentin, Frédéric Chibon, Sabrina Lodin, Thomas Filleron
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer
BMC Cancer
Background The value of chemotherapy in soft tissue sarcoma (STS) remains controversial. Several expert teams consider that chemotherapy provides a survival advantage and should be proposed in high-risk (HR) patients. However, the lack of accuracy in
Autor:
Jérôme Lemonnier, Bernard Asselain, Henri Roché, Joseph M. Anderson, Carl Yoshizawa, Diana B. Cherbavaz, Frederick L. Baehner, Magali Lacroix-Triki, Anne-Laure Martin, Thomas Filleron, Pierre Fumoleau, Lise Roca, Frédérique Penault-Llorca, Christine Sagan, Steven Shak
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer
BMC Cancer, BioMed Central, 2018, 18 (1), pp.526. ⟨10.1186/s12885-018-4331-8⟩
BMC Cancer, 2018, 18 (1), pp.526. ⟨10.1186/s12885-018-4331-8⟩
BMC Cancer
BMC Cancer, BioMed Central, 2018, 18 (1), pp.526. ⟨10.1186/s12885-018-4331-8⟩
BMC Cancer, 2018, 18 (1), pp.526. ⟨10.1186/s12885-018-4331-8⟩
Background The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate
Autor:
Jonathan Khalifa, Florence Dalenc, Eva Jouve, C. Massabeau, Raphaëlle Duprez-Paumier, Magali Lacroix Triki, Thomas Filleron
Publikováno v:
The Breast Journal. 22:510-519
The optimal management of patients with pathologically node-negative triple-negative breast cancer (pN0 TNBC) remains unclear. We hypothesized that lymph node irradiation (LNI; internal mammary chain/periclavicular irradiation) had an impact on outco
Autor:
Philippe Rochaix, Carine Valle, Thomas Filleron, Tom Lesluyes, S. Le Guellec, J.-M. Coindre, Gaëlle Pérot, E. Sarot, Frédéric Chibon, Thibaud Valentin
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(8)
Background Prediction of metastatic outcome in sarcomas is challenging for clinical management since they are aggressive and carry a high metastatic risk. A 67-gene expression signature, the Complexity INdex in SARComas (CINSARC), has been identified
Autor:
Roman K. Thomas, Oliver Gautschi, Julien Mazieres, Johannes M. Heuckmann, Sacha I. Rothschild, Fabrice Barlesi, Jürgen Wolf, Joachim Diebold, Pamela Biondani, Christian Spirig, L. Crinò, Gérard Zalcman, Damien Rouviere, Nicolas Pécuchet, Thomas Filleron, Julie Milia, Rafal Dziadziuszko, Anne-Marie C. Dingemans, Isabelle Monnet, Federico Cappuzzo, Benjamin Besse, Frauke Leenders, Luc Thiberville, Hervé Lena, Egbert F. Smit
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2015, 33 (9), pp.992-9
Journal of Clinical Oncology, American Society of Clinical Oncology, 2015, 33 (9), pp.992-9
Mazieres, J, Zalcman, G, Crino, L, Biondani, P, Barlesi, F, Filleron, T, Dingemans, A M C, Lena, H, Monnet, I, Rothschild, S I, Cappuzzo, F, Besse, B, Thiberville, L, Rouviere, D, Dziadziuszko, R, Smit, E F, Wolf, J, Spirig, C, Pecuchet, N, Leenders, F, Heuckmann, J M, Diebold, J, Milia, J D, Thomas, R K & Gautschi, O 2015, ' Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort ', Journal of Clinical Oncology, vol. 33, no. 9, pp. 992-999 . https://doi.org/10.1200/JCO.2014.58.3302
Journal of Clinical Oncology, 33(9), 992-999. American Society of Clinical Oncology
Journal of Clinical Oncology, 2015, 33 (9), pp.992-9
Journal of Clinical Oncology, American Society of Clinical Oncology, 2015, 33 (9), pp.992-9
Mazieres, J, Zalcman, G, Crino, L, Biondani, P, Barlesi, F, Filleron, T, Dingemans, A M C, Lena, H, Monnet, I, Rothschild, S I, Cappuzzo, F, Besse, B, Thiberville, L, Rouviere, D, Dziadziuszko, R, Smit, E F, Wolf, J, Spirig, C, Pecuchet, N, Leenders, F, Heuckmann, J M, Diebold, J, Milia, J D, Thomas, R K & Gautschi, O 2015, ' Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort ', Journal of Clinical Oncology, vol. 33, no. 9, pp. 992-999 . https://doi.org/10.1200/JCO.2014.58.3302
Journal of Clinical Oncology, 33(9), 992-999. American Society of Clinical Oncology
Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. Patients and Methods In the absence of a prospective clinical trial in Europe, we condu
Autor:
Anthony Al Hawat, Guillaume de Bonnecaze, Elie Serrano, Thomas Filleron, Sébastien Vergez, Benoit Chaput, Benjamin Vairel
Publikováno v:
Acta Oto-Laryngologica. 134:1259-1264
Endoscopic techniques seem to be safe approaches for the treatment of esthesioneuroblastomas (ENBs). However, they are intended for selected patients and require extensive experience in base of the skull surgery.ENB is a rare tumor of the nasal cavit
Autor:
D. Gangloff, Christine Chevreau, A. Ducassou, Philippe Rochaix, G. Ferron, Thomas Filleron, A. Modesto, C. Le Pechoux, S. Le Guellec, M. Delannes
Publikováno v:
European Journal of Surgical Oncology (EJSO). 40:187-192
To report on clinical outcome and toxicity profile after combined treatment that included radiation therapy (RT) in patients with localized sarcoma within an irradiated field.Individual clinical data from all consecutive patients diagnosed and treate
Autor:
Alejandra Martinez, Denis Querleu, Laurance Gladieff, Cristophe Pomel, Thomas Filleron, Marjolein De Cuypere, Gwenael Ferron, Mathieu Poilblanc, Eliane Mery
Publikováno v:
International Journal of Gynecologic Cancer. 24:48-53
ObjectiveThe aim of the study was to report on the oncologic outcome of the disease spread to celiac lymph nodes (CLNs) in advanced-stage ovarian cancer patients.MethodsAll patients who had CLN resection as part of their cytoreductive surgery for epi